Loading...

We've got a brand new version of Simply Wall St! Try it out

Ypsomed Holding

SWX:YPSN
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YPSN
SWX
CHF2B
Market Cap
  1. Home
  2. CH
  3. Healthcare
Company description

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
YPSN Share Price and Events
7 Day Returns
-3.7%
SWX:YPSN
0.7%
CH Medical Equipment
-0.4%
CH Market
1 Year Returns
1.8%
SWX:YPSN
33.3%
CH Medical Equipment
12.3%
CH Market
YPSN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ypsomed Holding (YPSN) -3.7% -9.5% 5.4% 1.8% -28.7% 51.4%
CH Medical Equipment 0.7% 2.5% 4.3% 33.3% 85.6% 109.4%
CH Market -0.4% 2.6% 6.7% 12.3% 21.5% 13.4%
1 Year Return vs Industry and Market
  • YPSN underperformed the Medical Equipment industry which returned 33.3% over the past year.
  • YPSN underperformed the Market in Switzerland which returned 12.3% over the past year.
Price Volatility
YPSN
Industry
5yr Volatility vs Market

YPSN Value

 Is Ypsomed Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ypsomed Holding to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ypsomed Holding.

SWX:YPSN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:YPSN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.84
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.84 (1 + (1- 18%) (9.77%))
0.938
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.938 * 5.96%)
8.86%

Discounted Cash Flow Calculation for SWX:YPSN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ypsomed Holding is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:YPSN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CHF, Millions) Source Present Value
Discounted (@ 8.86%)
2020 -18.00 Analyst x1 -16.53
2021 -8.00 Analyst x1 -6.75
2022 33.00 Analyst x1 25.58
2023 58.33 Est @ 76.76% 41.53
2024 90.25 Est @ 54.72% 59.02
2025 125.70 Est @ 39.28% 75.51
2026 161.50 Est @ 28.48% 89.12
2027 195.29 Est @ 20.92% 98.99
2028 225.80 Est @ 15.63% 105.14
2029 252.72 Est @ 11.92% 108.09
Present value of next 10 years cash flows CHF579.00
SWX:YPSN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CHF252.72 × (1 + 3.28%) ÷ (8.86% – 3.28%)
CHF4,669.61
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CHF4,669.61 ÷ (1 + 8.86%)10
CHF1,997.22
SWX:YPSN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CHF579.00 + CHF1,997.22
CHF2,576.22
Equity Value per Share
(CHF)
= Total value / Shares Outstanding
= CHF2,576.22 / 12.60
CHF204.41
SWX:YPSN Discount to Share Price
Calculation Result
Value per share (CHF) From above. CHF204.41
Current discount Discount to share price of CHF129.80
= -1 x (CHF129.80 - CHF204.41) / CHF204.41
36.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Ypsomed Holding is available for.
Intrinsic value
37%
Share price is CHF129.8 vs Future cash flow value of CHF204.41
Current Discount Checks
For Ypsomed Holding to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Ypsomed Holding's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Ypsomed Holding's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ypsomed Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ypsomed Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:YPSN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CHF CHF0.92
SWX:YPSN Share Price ** SWX (2019-11-13) in CHF CHF129.8
Switzerland Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 33.29x
Switzerland Market PE Ratio Median Figure of 171 Publicly-Listed Companies 19.37x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ypsomed Holding.

SWX:YPSN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:YPSN Share Price ÷ EPS (both in CHF)

= 129.8 ÷ 0.92

140.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ypsomed Holding is overvalued based on earnings compared to the CH Medical Equipment industry average.
  • Ypsomed Holding is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Ypsomed Holding's expected growth come at a high price?
Raw Data
SWX:YPSN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 140.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
64.2%per year
Switzerland Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.34x
Switzerland Market PEG Ratio Median Figure of 124 Publicly-Listed Companies 2.14x

*Line of best fit is calculated by linear regression .

SWX:YPSN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 140.41x ÷ 64.2%

2.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ypsomed Holding is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Ypsomed Holding's assets?
Raw Data
SWX:YPSN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CHF CHF29.83
SWX:YPSN Share Price * SWX (2019-11-13) in CHF CHF129.8
Switzerland Medical Equipment Industry PB Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 6.21x
Switzerland Market PB Ratio Median Figure of 214 Publicly-Listed Companies 1.65x
SWX:YPSN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:YPSN Share Price ÷ Book Value per Share (both in CHF)

= 129.8 ÷ 29.83

4.35x

* Primary Listing of Ypsomed Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ypsomed Holding is good value based on assets compared to the CH Medical Equipment industry average.
X
Value checks
We assess Ypsomed Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Ypsomed Holding has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

YPSN Future Performance

 How is Ypsomed Holding expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
64.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ypsomed Holding expected to grow at an attractive rate?
  • Ypsomed Holding's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Ypsomed Holding's earnings growth is expected to exceed the Switzerland market average.
  • Ypsomed Holding's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:YPSN Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:YPSN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 64.2%
SWX:YPSN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 10.1%
Switzerland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 38.7%
Switzerland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:YPSN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:YPSN Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 598 1
2023-03-31 555 1
2022-03-31 527 103 63 2
2021-03-31 470 79 40 2
2020-03-31 405 78 18 2
2019-11-14
SWX:YPSN Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2019-09-30 386 39 12
2019-06-30 420 49 36
2019-03-31 454 60 60
2018-12-31 483 68 72
2018-09-30 511 76 85
2018-06-30 489 65 68
2018-03-31 466 53 52
2017-12-31 442 62 50
2017-09-30 418 70 47
2017-06-30 404 73 47
2017-03-31 390 75 46
2016-12-31 377 77 45

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ypsomed Holding's earnings are expected to grow significantly at over 20% yearly.
  • Ypsomed Holding's revenue is expected to grow by 10.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:YPSN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Ypsomed Holding Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:YPSN Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31 5.01 5.42 4.59 2.00
2021-03-31 3.18 3.27 3.08 2.00
2020-03-31 1.46 1.51 1.40 2.00
2019-11-14
SWX:YPSN Past Financials Data
Date (Data in CHF Millions) EPS *
2019-09-30 0.92
2019-06-30 2.85
2019-03-31 4.77
2018-12-31 5.75
2018-09-30 6.73
2018-06-30 5.43
2018-03-31 4.14
2017-12-31 3.94
2017-09-30 3.75
2017-06-30 3.71
2017-03-31 3.67
2016-12-31 3.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Ypsomed Holding is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Ypsomed Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ypsomed Holding has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

YPSN Past Performance

  How has Ypsomed Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ypsomed Holding's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ypsomed Holding's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Ypsomed Holding's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Ypsomed Holding's 1-year earnings growth is negative, it can't be compared to the CH Medical Equipment industry average.
Earnings and Revenue History
Ypsomed Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ypsomed Holding Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:YPSN Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 385.69 11.65 90.01
2019-06-30 419.73 35.89 90.05
2019-03-31 453.77 60.14 90.09
2018-12-31 482.61 72.44 89.65
2018-09-30 511.46 84.75 89.22
2018-06-30 488.79 68.40 85.66
2018-03-31 466.12 52.06 82.10
2017-12-31 441.83 49.64 78.44
2017-09-30 417.53 47.22 74.78
2017-06-30 403.54 46.73 73.83
2017-03-31 389.56 46.25 72.88
2016-12-31 377.04 44.64 69.77
2016-09-30 364.53 43.03 66.66
2016-06-30 350.73 39.42 64.43
2016-03-31 336.92 35.81 62.20
2015-12-31 326.40 30.66 61.29
2015-09-30 315.89 25.51 60.39
2015-06-30 311.26 22.45 60.30
2015-03-31 306.63 19.40 60.21
2014-12-31 299.97 18.75 59.19
2014-09-30 293.31 18.11 58.18
2014-06-30 284.78 15.86 56.80
2014-03-31 276.26 13.61 55.41
2013-12-31 266.28 8.91 55.40
2013-09-30 256.29 4.21 55.39
2013-06-30 250.43 2.93 54.76
2013-03-31 244.57 1.65 54.12
2012-12-31 245.03 2.30 53.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Ypsomed Holding has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Ypsomed Holding used its assets less efficiently than the CH Medical Equipment industry average last year based on Return on Assets.
  • Ypsomed Holding's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Ypsomed Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ypsomed Holding has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

YPSN Health

 How is Ypsomed Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ypsomed Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ypsomed Holding's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Ypsomed Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ypsomed Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ypsomed Holding Company Filings, last reported 1 month ago.

SWX:YPSN Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 375.95 160.98 23.99
2019-06-30 375.95 160.98 23.99
2019-03-31 378.80 122.00 12.08
2018-12-31 378.80 122.00 12.08
2018-09-30 376.28 93.00 35.02
2018-06-30 376.28 93.00 35.02
2018-03-31 341.54 59.00 32.11
2017-12-31 341.54 59.00 32.11
2017-09-30 303.81 52.00 35.45
2017-06-30 303.81 52.00 35.45
2017-03-31 301.80 37.00 38.88
2016-12-31 301.80 37.00 38.88
2016-09-30 277.35 45.00 27.81
2016-06-30 277.35 45.00 27.81
2016-03-31 267.84 49.00 25.51
2015-12-31 267.84 49.00 25.51
2015-09-30 249.86 15.00 18.75
2015-06-30 249.86 15.00 18.75
2015-03-31 240.64 71.00 16.24
2014-12-31 240.64 71.00 16.24
2014-09-30 234.79 20.00 18.26
2014-06-30 234.79 20.00 18.26
2014-03-31 228.16 20.00 16.16
2013-12-31 228.16 20.00 16.16
2013-09-30 219.56 20.00 14.91
2013-06-30 219.56 20.00 14.91
2013-03-31 217.38 20.00 9.61
2012-12-31 217.38 20.00 9.61
  • Ypsomed Holding's level of debt (42.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (8.8% vs 42.8% today).
  • Debt is well covered by operating cash flow (24.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 39x coverage).
X
Financial health checks
We assess Ypsomed Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ypsomed Holding has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

YPSN Dividends

 What is Ypsomed Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.42%
Current annual income from Ypsomed Holding dividends. Estimated to be 1.16% next year.
If you bought CHF2,000 of Ypsomed Holding shares you are expected to receive CHF8 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Ypsomed Holding's pays a lower dividend yield than the bottom 25% of dividend payers in Switzerland (1.85%).
  • Ypsomed Holding's dividend is below the markets top 25% of dividend payers in Switzerland (3.63%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:YPSN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Switzerland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 163 Stocks 2.9%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.8%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:YPSN Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31 3.03 2.00
2021-03-31 0.93 2.00
2020-03-31 0.58 2.00
2019-11-14
SWX:YPSN Past Annualized Dividends Data
Date (Data in CHF) Dividend per share (annual) Avg. Yield (%)
2019-05-23 0.550 0.421
2018-05-15 1.400 1.058
2017-05-24 1.300 0.798
2016-05-20 1.000 0.532
2015-05-20 0.600 0.493
2014-05-27 0.300 0.349
2013-05-22 0.200 0.307
2012-05-24 0.200 0.368
2011-05-17 0.200 0.375
2010-05-26 0.250 0.440
2009-03-31 0.600 0.873

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ypsomed Holding is not paying a notable dividend for Switzerland, therefore no need to check if the payments are stable.
  • Ypsomed Holding is not paying a notable dividend for Switzerland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Ypsomed Holding's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Ypsomed Holding's dividends as it is not paying a notable one for Switzerland.
Future Payout to shareholders
  • No need to calculate the sustainability of Ypsomed Holding's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
X
Income/ dividend checks
We assess Ypsomed Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ypsomed Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ypsomed Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

YPSN Management

 What is the CEO of Ypsomed Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Simon Michel
COMPENSATION CHF850,900
AGE 42
TENURE AS CEO 5.3 years
CEO Bio

Mr. Simon Michel has been the Chief Executive Officer of Ypsomed Holding AG since July 2014. Mr. Michel serves as a Senior Vice President of Marketing & Sales for Ypsomed Holding AG and is responsible for the business development and marketing of the injection, infusion and blood glucose meters as well as pen needles. He has been working with Ypsomed since October 2006 and has been a Member of management since 2008. He served as a Finance Director of International, MIM at New Look Group Limited. He served as Senior Vice President of Marketing at Ypsomed Holding AG since October 2006 and also served as its Senior Vice President of Business Development. Mr. Michel served as Head of the Infusion Business Division at Ypsomed Holding AG. From 2003 to 2006, he worked for Orange Telecommunications in Zurich and Lausanne, was responsible for, among other things, the introduction and marketing of UMTS. Mr. Michel has been a Director of Sphinx Werkzeuge AG since 2006. He has been a member of executive committee of the local trade and industry association since 2008. He studied Masters with a focus on Media and Communications Management and Economics at the University of St. Gallen.

CEO Compensation
  • Simon's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Simon's remuneration is about average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Ypsomed Holding management team in years:

8.3
Average Tenure
54
Average Age
  • The average tenure for the Ypsomed Holding management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Simon Michel

TITLE
Chief Executive Officer
COMPENSATION
CHF851K
AGE
42
TENURE
5.3 yrs

Niklaus Ramseier

TITLE
Chief Financial Officer
AGE
56
TENURE
17.8 yrs

Frank Mengis

TITLE
Chief Operating Officer
AGE
55
TENURE
4.1 yrs

Hans-Ulrich Lehmann

TITLE
Senior Vice President of Technology
AGE
53
TENURE
8.8 yrs

Thomas Kutt

TITLE
Head of Investor Relations

Beat Maurer

TITLE
Senior VP of Legal Services & Intellectual Property and Secretary of the Board
AGE
61
TENURE
27.8 yrs

Michael Zaugg

TITLE
Senior Vice President of Human Resources
AGE
47
TENURE
2.6 yrs

Ulrike Bauer

TITLE
Senior Vice President of Marketing & Sales Delivery Systems
AGE
50
TENURE
18.8 yrs

Eberhard Bauer

TITLE
Senior Vice President of Marketing & Sales - Diabetes Care
AGE
59
TENURE
7.8 yrs
Board of Directors Tenure

Average tenure and age of the Ypsomed Holding board of directors in years:

6.6
Average Tenure
64.5
Average Age
  • The tenure for the Ypsomed Holding board of directors is about average.
Board of Directors

Willy Michel

TITLE
Chairman of the Board
COMPENSATION
CHF202K
AGE
72
TENURE
16.8 yrs

Anton Kräuliger

TITLE
Vice Chairman
COMPENSATION
CHF123K
AGE
73
TENURE
11.8 yrs

Paul Fonteyne

TITLE
Director
COMPENSATION
CHF122K
AGE
57
TENURE
1.4 yrs

Martin Münchbach

TITLE
Director
AGE
49
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Ypsomed Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ypsomed Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

YPSN News

Simply Wall St News

Should You Worry About Ypsomed Holding AG's (VTX:YPSN) CEO Pay?

See our latest analysis for Ypsomed Holding How Does Simon Michel's Compensation Compare With Similar Sized Companies? … At the time of writing our data says that Ypsomed Holding AG has a market cap of CHF1.6b, and is paying total annual CEO compensation of CHF851k. … SWX:YPSN CEO Compensation, September 4th 2019Is Ypsomed Holding AG Growing?

Simply Wall St -

Ypsomed Holding AG (VTX:YPSN): Commentary On Fundamentals

SWX:YPSN Income Statement, August 23rd 2019 Next Steps: For Ypsomed Holding, there are three pertinent aspects you should further research: Future Outlook: What are well-informed industry analysts predicting for YPSN’s future growth? … The intrinsic value infographic in our free research report helps visualize whether YPSN is currently mispriced by the market. … Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of YPSN?

Simply Wall St -

What Kind Of Shareholders Own Ypsomed Holding AG (VTX:YPSN)?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Ypsomed Holding has a market capitalization of CHF1.6b, so we would expect some institutional investors to have noticed the stock. … See our latest analysis for Ypsomed Holding SWX:YPSN Ownership Summary, August 13th 2019 What Does The Institutional Ownership Tell Us About Ypsomed Holding? … Insider Ownership Of Ypsomed Holding While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Here's What Ypsomed Holding AG's (VTX:YPSN) P/E Ratio Is Telling Us

We'll look at Ypsomed Holding AG's (VTX:YPSN) P/E ratio and reflect on what it tells us about the company's share price. … The formula for P/E is: Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS) Or for Ypsomed Holding: P/E of 27.45 = CHF131 ÷ CHF4.77 (Based on the year to March 2019.) Is A High Price-to-Earnings Ratio Good? … The Verdict On Ypsomed Holding's P/E Ratio Ypsomed Holding trades on a P/E ratio of 27.5, which is above its market average of 18.4.

Simply Wall St -

If You Had Bought Ypsomed Holding (VTX:YPSN) Stock Five Years Ago, You Could Pocket A 60% Gain Today

To wit, the Ypsomed Holding share price has climbed 60% in five years, easily topping the market return of 13% (ignoring dividends). … During five years of share price growth, Ypsomed Holding achieved compound earnings per share (EPS) growth of 35% per year. … As it happens, Ypsomed Holding's TSR for the last 5 years was 65%, which exceeds the share price return mentioned earlier.

Simply Wall St -

These 4 Measures Indicate That Ypsomed Holding (VTX:YPSN) Is Using Debt Reasonably Well

We note that Ypsomed Holding AG (VTX:YPSN) does have debt on its balance sheet. … SWX:YPSN Historical Debt, July 1st 2019 How Strong Is Ypsomed Holding's Balance Sheet? … Since Ypsomed Holding does have net debt, we think it is worthwhile for shareholders to keep an eye on the balance sheet, over time.

Simply Wall St -

Does Ypsomed Holding AG's (VTX:YPSN) Past Performance Indicate A Stronger Future?

View our latest analysis for Ypsomed Holding Were YPSN's earnings stronger than its past performances and the industry? … While Ypsomed Holding has a good historical track record with positive growth and profitability, there's no certainty that this will extrapolate into the future. … I recommend you continue to research Ypsomed Holding to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for YPSN’s future growth?

Simply Wall St -

Is Ypsomed Holding AG's (VTX:YPSN) Future Growth Already Accounted For In Today's Price?

Ypsomed Holding is available at price-to-earnings ratio of 25.57x, showing us it is undervalued based on its latest annual earnings update compared to the Medical Equipment average of 29.92x , and overvalued compared to the CH market average ratio of 18.36x. … A PE ratio of 25.57x and expected year-on-year earnings growth of 11% give Ypsomed Holding a quite high PEG ratio of 2.25x. … So, when we include the growth factor in our analysis, Ypsomed Holding appears overvalued , based on the fundamentals.

Simply Wall St -

Ypsomed Holding AG (VTX:YPSN) Has A ROE Of 16%

The formula for return on equity is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Ypsomed Holding: 16% = CHF60m ÷ CHF379m (Based on the trailing twelve months to March 2019.) Most readers would understand what net profit is, but it’s worth explaining the concept of shareholders’ equity. … Does Ypsomed Holding Have A Good Return On Equity? … Ypsomed Holding's Debt And Its 16% ROE While Ypsomed Holding does have some debt, with debt to equity of just 0.32, we wouldn't say debt is excessive.

Simply Wall St -

Why Ypsomed Holding AG (VTX:YPSN) Could Have A Place In Your Portfolio

Want to participate in a short research study? … Help shape the future of investing tools and you could win a $250 gift card! … In the case of Ypsomed Holding AG (VTX:YPSN), there's

Simply Wall St -

YPSN Company Info

Description

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others segments. The Ypsomed Delivery Systems segment offers various injection systems, such as pen injectors, auto injectors, and dual-chamber pens, as well as insulin pens, other diabetes pens, pens for growth hormones, and other pens. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The Others segment offers precision turned parts. In addition, it offers contract manufacturing and other services. The company markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, other European countries, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

Details
Name: Ypsomed Holding AG
YPSN
Exchange: SWX
Founded: 1984
CHF1,648,466,252
12,602,953
Website: http://www.ypsomed.com
Address: Ypsomed Holding AG
Brunnmattstrasse 6,
Burgdorf,
Bern, 3401,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX YPSN Registered Shares SIX Swiss Exchange CH CHF 22. Sep 2004
DB OWX Registered Shares Deutsche Boerse AG DE EUR 22. Sep 2004
LSE 0QLQ Registered Shares London Stock Exchange GB CHF 22. Sep 2004
Number of employees
Current staff
Staff numbers
1,700
Ypsomed Holding employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 20:32
End of day share price update: 2019/11/13 00:00
Last estimates confirmation: 2019/11/08
Last earnings filing: 2019/11/05
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.